8th Annual Complement-Based Drug Development Summit
With the community hailing the latest FDA-approved therapeutic with Novartis’ inhibitor of the alternative complement for PNH, which inhibitor will be the next to harness the complement system for the development of groundbreaking therapies?
With assets in nephrology, ophthalmology, neurodegeneration, and inflammation all progressing through to the clinic, the immunology landscape is preparing to be shaken up with companies making huge strides to achieve and improve the efficacy of complement-targeted therapies.
Join 100+ industry leaders, scientists, and clinicians at the premier, end-to-end, 8th Complement-Based Drug Development Summit to shape the future of complement-targeted therapies. Across 3 days of content, you can expect discussions spanning:
- Strategic targeting and preclinical breakthroughs for the next generation of complement inhibitors and comprehensive insights into the complexities of the complement pathways and selection of inhibition targets
- Navigating complement clinical trials and exploring indication expansion strategy for complement inhibitors beyond their initial disease indication
- Exploring the potential for combination therapies to overcome compensatory mechanisms and ensure patient comfort
- Moving from targeting rare disease with complement inhibitors to larger patient populations
- Navigating efficacy and safety of complement inhibitors to bring safer and more tolerable therapies to patients faster
Download the agenda here: https://ter.li/otk47b
Don’t miss out on this premiere event - register now and enjoy up to 20% off if you bring your colleagues! Register online here: https://ter.li/r17w9p
Dates: December 10 - 12, 2024
Location: Hilton Boston Logan Airport, One Hotel Drive, Boston, MA 02128, United States
Event guide: https://ter.li/otk47b
